Eloralintide
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
Eli Lilly · Phase 2 · Recruiting · Enrollment 400
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Macupatide Dose 1 | n/r | n/r | n/r | n/r |
| Eloralintide Dose 1 | n/r | n/r | n/r | n/r |
| Macupatide Dose 1 + Eloralintide Dose 1 | n/r | n/r | n/r | n/r |
| Eloralintide Dose 2 | n/r | n/r | n/r | n/r |
| Macupatide Dose 1 + Eloralintide Dose 2 | n/r | n/r | n/r | n/r |
| Eloralintide Dose 3 | n/r | n/r | n/r | n/r |
| Macupatide Dose 2 + Eloralintide Dose 3 | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
Not shown
- Macupatide Dose 1: endpoint not reported
- Eloralintide Dose 1: endpoint not reported
- Macupatide Dose 1 + Eloralintide Dose 1: endpoint not reported
- Eloralintide Dose 2: endpoint not reported
- Macupatide Dose 1 + Eloralintide Dose 2: endpoint not reported
- Eloralintide Dose 3: endpoint not reported
- Macupatide Dose 2 + Eloralintide Dose 3: endpoint not reported
- Placebo: endpoint not reported